# Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)

> **NCT05524311** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 16 (actual)

## Conditions studied

- Juvenile Dermatomyositis

## Interventions

- **DRUG:** Baricitinib
- **BIOLOGICAL:** pharmacokinetics study
- **BIOLOGICAL:** dosage of cytokines
- **BIOLOGICAL:** transcriptomic analysis
- **BEHAVIORAL:** Parent version of the Child Health Questionnaire (CHQ)
- **BEHAVIORAL:** Childhood Health Assessment Questionnaire
- **BIOLOGICAL:** Pregnancy test

## Key facts

- **NCT ID:** NCT05524311
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-10
- **Primary completion:** 2025-05-13
- **Final completion:** 2026-01-02
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05524311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05524311, "Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05524311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*